← Pacira BioSciences, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $276.4m |
$286.6m
+3.71%
|
$332.4m
+15.98%
|
$418.9m
+26.02%
|
$426.6m
+1.84%
|
$539.0m
+26.34%
|
$666.8m
+23.72%
|
$675.0m
+1.22%
|
$1.4b
+107.14%
|
$726.4m
-48.04%
|
$746.2m
+2.72%
|
|
| Cost of Goods and Services Sold | $110.1m |
$87.9m
-20.15%
|
$86.8m
-1.22%
|
$106.7m
+22.88%
|
$117.3m
+9.95%
|
$140.3m
+19.54%
|
$199.3m
+42.09%
|
$184.7m
-7.34%
|
$170.4m
-7.71%
|
$149.7m
-12.13%
|
$155.2m
+3.61%
|
|
| Gross Profit (Calculated) | $166.3m |
$198.7m
+19.52%
|
$245.6m
+23.59%
|
$312.2m
+27.13%
|
$309.3m
-0.94%
|
$398.7m
+28.91%
|
$467.5m
+17.26%
|
$490.3m
+4.87%
|
$1.2b
+150.40%
|
$576.7m
-53.03%
|
— | |
| Research and Development Expense | $45.7m | $57.3m | $55.7m | $72.1m | $59.4m | $55.5m | $84.8m | $76.3m | $81.6m | $117.3m | $121.7m | |
| Selling, General and Administrative Expense | $152.6m | $161.5m | $177.3m | $200.8m | $193.5m | $199.3m | $254.5m | $269.4m | $294.1m | $368.8m | $379.2m | |
| Amortization of Intangible Assets | $100k | $0 | $0 | $5.7m | $7.9m | $13.6m | $57.3m | $57.3m | $57.3m | $57.3m | — | |
| Operating Expenses | $308.4m | $311.6m | $321.4m | $410.5m | — | — | — | — | — | — | $727.4m | |
| Operating Income (Loss) | ($32.0m) |
($24.9m)
+22.13%
|
$15.9m
+163.82%
|
$10.5m
-34.15%
|
$46.4m
+342.27%
|
$89.9m
+94.01%
|
$60.0m
-33.25%
|
$87.7m
+46.07%
|
($73.4m)
-183.69%
|
$19.2m
+126.16%
|
$18.7m
-2.46%
|
|
| Interest Expense, Debt | $7.1m | $18.0m | $21.9m | $23.6m | $25.7m | $31.8m | $40.0m | $20.3m | $16.6m | $17.4m | $13.3m | |
| Gain (Loss) on Investments | — | — | ($854k) | ($4.3m) | $1.6m | ($2.7m) | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($82k) | $167k | ($888k) | ($5.0m) | $2.9m | ($2.7m) | ($11.3m) | ($186k) | ($373k) | ($6.6m) | — | |
| Interest Expense (non-operating) | $7.1m | $18.0m | $21.9m | $23.6m | $25.7m | $31.8m | $40.0m | $20.3m | $16.6m | $17.4m | $13.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($36.3m) | ($39.9m) | $5.2m | ($71k) | $17.0m | $64.8m | $21.1m | $66.3m | ($65.3m) | $19.6m | $17.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($37.8m) | ($42.5m) | ($425k) | ($10.7m) | $20.1m | $56.4m | $13.3m | $61.7m | ($63.1m) | $16.9m | $17.6m | |
| Current Income Tax Expense (Benefit) | $105k | $140k | $46k | $2.1m | $1.2m | $3.6m | $5.3m | $4.1m | $15.8m | $3.4m | $3.0m | |
| Income Tax Expense (Benefit) | $105k | $140k | $46k | $268k | ($125.4m) | $14.4m | ($2.6m) | $19.7m | $36.5m | $9.8m | $3.0m | |
| Net Income (Loss) Attributable to Parent | ($37.9m) |
($42.6m)
-12.28%
|
($471k)
+98.89%
|
($11.0m)
-2238.85%
|
$145.5m
+1421.01%
|
$42.0m
-71.15%
|
$15.9m
-62.10%
|
$42.0m
+163.72%
|
($99.6m)
-337.30%
|
$7.0m
+107.07%
|
$14.6m
+108.10%
|
|
| Earnings Per Share, Basic | ($1.02) | ($1.07) | ($0.01) | ($0.27) | $3.41 | $0.95 | $0.35 | $0.91 | ($2.15) | $0.16 | $0.35 | |
| Earnings Per Share, Diluted | ($1.02) | ($1.07) | ($0.01) | ($0.27) | $3.33 | $0.92 | $0.34 | $0.89 | ($2.15) | $0.16 | $0.35 | |
| Weighted Average Number of Shares Outstanding, Basic | 37.2m | 39.8m | 40.9m | — | 42.7m | 44.3m | 45.5m | 46.2m | 46.2m | 44.6m | 41.6m | |
| Weighted Average Number of Shares Outstanding, Diluted | 37.2m | 39.8m | — | 41.5m | 43.7m | 45.6m | 46.5m | 52.0m | 46.2m | 45.0m | 42.4m | |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related Costs | — | — | — | — | — | — | — | — | — | $2.9m | — | |
| Costs and Expenses | — | — | — | — | $383.3m | $451.6m | $606.8m | $587.3m | — | $707.2m | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | — | $163.2m | $0 | $0 | |
| Litigation Settlement Loss | — | — | — | — | — | — | — | — | — | $7.0m | — | |
| Realized Investment Gains (Losses) | — | — | $900k | — | — | — | — | — | — | — | — |